Treatment of TF containing EC-EVs with an antibody against TF drastically reduced EV thrombogenicity [115].Contemporary research has identified a threshold of EC-EVs containing TF to negatively impact pulmonary lung capacity and exacerbate the severity of disease for individuals infected with COVID-19 [116]. Here, TF is linked to COVID-19.